According to the deep-dive market assessment study conducted by Growth+Reports, the global dexamethasone market was pegged at ~US$ 500 million in 2020. The market is expected to witness a CAGR of ~6% from 2021 to 2031.

The rapid spread of coronavirus disease (COVID-19) across almost every country worldwide, has resulted in severe outcomes, across all these regions. The first case of COVID-19 was found in Dec 2019, by the end of Dec 2020, the count has surged to more than 90.3 million globally. Dexamethasone is a medicine that decreases inflammation by producing anti-inflammatory hormones by the human body. To fight off the novel coronavirus, the body’s immune system causes inflammation to occur. In its response, the immune system sometimes goes into overdrive (proving to be fatal in some cases) and dexamethasone helps to calm this effect. A randomized, controlled clinical trial in the United Kingdom has found dexamethasone can save the lives of people seriously ill with COVID-19. Shortly after the results were released, the U.K government immediately authorized the use of dexamethasone for patients hospitalized with COVID-19 who required oxygen, including those on ventilators.

To access the Sample PDF of this research study, please request here: https://growthplusreports.com/inquiry/request-sample/dexamethasone-market/7637

Some of the prominent players operating in the dexamethasone market includes: -
• Novartis AG
• Pfizer Inc
• Cadila Pharmaceuticals
• Sun Pharmaceutical Industries Ltd
• Allergan
• Zydus Cadila
• Fresenius Kabi USA
• GLS pharma ltd
• Hikma Pharmaceuticals Plc
• Ocular Therapeutix

Browse the full report now: https://growthplusreports.com/report/dexamethasone-market/7637

About Us:
Growth+Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth+ portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis, and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.